ライフサイエンスコーパス: cerebrovascular disease

1 ted by markers of both neurodegeneration and cerebrovascular disease.

2 BP produced by treatment among patients with cerebrovascular disease.

3 ssociation between vitamin D and subclinical cerebrovascular disease.

4 an increasing developmental basis for human cerebrovascular disease.

5 k for dementia later in life, independent of cerebrovascular disease.

6 ventricular arrhythmias, heart failure, and cerebrovascular disease.

7 eased risk of clinical stroke or subclinical cerebrovascular disease.

8 ment of pregnancy, and strategies to prevent cerebrovascular disease.

9 sorders should be targeted by treatments for cerebrovascular disease.

10 demia, diabetes, coronary heart disease, and cerebrovascular disease.

11 volved, especially in the absence of obvious cerebrovascular disease.

12 ronic atrial fibrillation and peripheral and cerebrovascular disease.

13 , two fundamental challenges in the field of cerebrovascular disease.

14 a 1 gene (COL4A1) cause dominantly inherited cerebrovascular disease.

15 n patients presenting with symptoms of acute cerebrovascular disease.

16 llelic series of COL4A1 mutations that cause cerebrovascular disease.

17 tion much like mutations that cause familial cerebrovascular disease.

18 rvation of gait speed in elderly people with cerebrovascular disease.

19 ld cognitive impairment maps more closely to cerebrovascular disease.

20 ial cell-derived exosomes in atherosclerotic cerebrovascular disease.

21 entify precise sequence variants influencing cerebrovascular disease.

22 bclasses to risk of both coronary artery and cerebrovascular disease.

23 im of most treatments for cardiovascular and cerebrovascular disease.

24 ts in patients with symptomatic coronary and cerebrovascular disease.

25 lly increase the risk for cardiovascular and cerebrovascular disease.

26 s a snapshot of a rapidly evolving aspect of cerebrovascular disease.

27 ple with Alzheimer's disease have concurrent cerebrovascular disease.

28 to CABG or related to other factors such as cerebrovascular disease.

29 orders in patients with clinical evidence of cerebrovascular disease.

30 ut only a modest burden of known coronary or cerebrovascular disease.

31 s a major risk factor for cardiovascular and cerebrovascular disease.

32 rt failure, peripheral vascular disease, and cerebrovascular disease.

33 e with increased risk for cardiovascular and cerebrovascular disease.

34 ld be useful for treatment and prevention of cerebrovascular disease.

35 ly onset of TAAD and occlusive moyamoya-like cerebrovascular disease.

36 lin sensitivity, might benefit patients with cerebrovascular disease.

37 cribed for patients with coronary artery and cerebrovascular disease.

38 may offer a potential therapeutic target in cerebrovascular disease.

39 cans that most commonly reflect small vessel cerebrovascular disease.

40 team, pancreas cold ischemia time, recipient cerebrovascular disease.

41 associated with increased cardiovascular and cerebrovascular disease.

42 rologic diagnosis, particularly headache and cerebrovascular disease.

43 le for myeloperoxidase in the progression of cerebrovascular disease.

44 s to neuronal injury during stroke and other cerebrovascular diseases.

45 n clinical application on cardiovascular and cerebrovascular diseases.

46 s, history of CVA, hyperlipidemia, and other cerebrovascular diseases.

47 nt of therapeutics for neuroinflammatory and cerebrovascular diseases.

48 development and a potential drug target for cerebrovascular diseases.

49 ed to train physicians specifically to treat cerebrovascular diseases.

50 participants, 4432 of whom were people with cerebrovascular diseases.

51 sion (OR 2.3, 95% CI 1.7-3.0) in adults with cerebrovascular diseases.

52 oxidative stress-mediated cardiovascular and cerebrovascular diseases.

53 parameter for treatment decisions in chronic cerebrovascular diseases.

54 gly associated with concomitant coronary and cerebrovascular diseases.

55 95% confidence interval: 0.89, 0.96) and for cerebrovascular disease = 0.93 (95% confidence interval:

56 6 x (renal insufficiency) + 0.46 x (previous cerebrovascular disease) + 0.352 x (prior tobacco use) +

57 on, 0.77 (95% CI: 0.65 to 0.93) for ischemic cerebrovascular disease, 0.71 (95% CI: 0.58 to 0.88) for

58 blood pressure-related deaths were caused by cerebrovascular diseases: 1.86 million (1.76-1.96) total

59 , congestive heart failure 2.65 (2.29-3.06), cerebrovascular disease 10.02 (9.08-11.05), insulin ther

60 VD deaths), hypertensive diseases (27%), and cerebrovascular diseases (10%).

61 ry artery disease (30.0%, 32.9%, and 34.3%), cerebrovascular disease (11.7%, 10.8%, and 17.6%), and v

62 h a partner (3.16; 2.71-3.69), those without cerebrovascular disease (2.23; 2.08-2.39), and those wit

63 eaths, with ischemic heart disease (31%) and cerebrovascular diseases (30%) being the leading CVD cau

64 235.7 deaths per 100000 persons) and 1.7 for cerebrovascular disease (40.3 vs 68.1 deaths per 100000

65 isease (44%), a psychiatric diagnosis (42%), cerebrovascular disease (41%), cardiac arrhythmias (40%)

66 with MPN versus controls (16.8% v 15.2%) or cerebrovascular disease (5.6% v 5.2%).

67 luded prodromal Alzheimer disease (8.2%) and cerebrovascular disease (5.7%).

68 itourinary infection (10.1%), sepsis (7.1%), cerebrovascular disease (5.8%), and pulmonary embolism (

69 S caused the most deaths (29.1%) followed by cerebrovascular disease (7.5%) and lower respiratory inf

70 , a 1.20-fold (95% CI: 1.15, 1.25) hazard of cerebrovascular disease, a 2.14-fold (95% CI: 2.06, 2.22

71 0.72; 95% CI: 0.55 to 0.94; p = 0.02), acute cerebrovascular disease (adjusted OR: 0.36; 95% CI: 0.31

72 dependent risk factor for cardiovascular and cerebrovascular diseases (adjusted HR, 2.27 [95% CI, .97

73 gic measures; however, high CLS men had less cerebrovascular disease after accounting for vascular ri

74 Ischemic heart disease and cerebrovascular disease age-standardized death rates (as

75 forms of noncardiac vascular disease except cerebrovascular disease alone.

76 irment in LLD seems to be related to greater cerebrovascular disease along with abnormalities in immu

77 CSVT requires greatly improved awareness of cerebrovascular disease among primary providers, who are

78 d atherosclerosis, dyslipidemia, cardio- and cerebrovascular disease, amputation, poor quality of lif

79 on in progressive vascular changes common to cerebrovascular disease and AD.

80 Cerebrovascular disease and Alzheimer disease (AD) frequ

81 ation counteracts the deleterious effects of cerebrovascular disease and Alzheimer's disease and high

82 ical impairment associated with small vessel cerebrovascular disease and Alzheimer's disease While th

83 on pathologies associated with brain ageing, cerebrovascular disease and Alzheimer's disease, and par

84 occurs in nephrosclerosis, several facets of cerebrovascular disease and cognitive decline are explai

85 ll disease in children is the development of cerebrovascular disease and cognitive impairment, and th

86 ions of neurodegenerative abnormalities with cerebrovascular disease and cognitive performance indica

87 ty and efficacy of endovascular treatment of cerebrovascular disease and concerns in anesthesia manag

88 ed neuroimaging findings in individuals with cerebrovascular disease and dementia, and in normal agei

89 of the association between these lesions and cerebrovascular disease and dementia.

90 Higher age, congestive heart failure, cerebrovascular disease and diabetes mellitus were indep

91 col designed to obtain a cohort enriched for cerebrovascular disease and elevated vascular risk.

92 prevalent in people with clinically manifest cerebrovascular disease and have been shown to increase

93 n addition to Alzheimer's disease, including cerebrovascular disease and hippocampal sclerosis.

94 ular COL4A1, or both, contribute to sporadic cerebrovascular disease and ICH.

95 of hypertonic saline in patients with severe cerebrovascular disease and impending intracranial hyper

96 system disorders, including highly penetrant cerebrovascular disease and intracerebral hemorrhage (IC

97 Covert cerebrovascular disease and its consequences on cognitiv

98 novel approaches to slow the progression of cerebrovascular disease and lessen both the frequency an

99 ld mandate inclusions of imaging studies for cerebrovascular disease and measures of homocysteine, fo

100 heart failure, or combination of preexisting cerebrovascular disease and mild cognitive impairment in

101 dysfunction may underlie depression both in cerebrovascular disease and neurodegenerative disorders.

102 detecting depressed mood in individuals with cerebrovascular disease and of developing more aggressiv

103 VD), including coronary heart disease (CHD), cerebrovascular disease and peripheral arterial disease.

104 function among individuals with established cerebrovascular disease and preserved estimated glomerul

105 have documented a close relationship between cerebrovascular disease and risk of Alzheimer's disease.

106 d provide insight into inflammation-mediated cerebrovascular disease and stroke.

107 c, studies on the role of the Hp genotype in cerebrovascular disease and the implications for worseni

108 15 provinces had cerebrovascular disease and two (Hong Kong and Macao) ha

109 Cerebrovascular disease and vascular risk factors are as

110 technology has a great impact on research in cerebrovascular diseases and still has various applicati

111 alization for or death from CHD, 25 426 from cerebrovascular disease, and 249 426 from hypertensive d

112 emic heart disease, 1,064 developed ischemic cerebrovascular disease, and 3,807 died during follow-up

113 heart failure, 84% had hypertension, 30% had cerebrovascular disease, and 8% had dementia.

114 lar disease: 345 coronary heart disease, 117 cerebrovascular disease, and 98 peripheral arterial dise

115 with increased risk of cognitive impairment, cerebrovascular disease, and Alzheimer's disease, but it

116 diabetes, dementia, ischaemic heart disease, cerebrovascular disease, and cancer because of increased

117 e matter hyperintensities (WMHs) represented cerebrovascular disease, and cerebrospinal fluid beta-am

118 ation class III/IV, antiarrhythmic drug use, cerebrovascular disease, and chronic kidney disease stag

119 id congestive heart failure, cardiomyopathy, cerebrovascular disease, and chronic lung disease.

120 metabolic syndrome, chronic kidney disease, cerebrovascular disease, and diabetes mellitus.

121 Risk of CHD, cerebrovascular disease, and heart failure in normal wei

122 had a higher risk of coronary heart disease, cerebrovascular disease, and heart failure than normal w

123 We examined CHD, cerebrovascular disease, and hypertensive disease risks

124 art disease, myocardial infarction, ischemic cerebrovascular disease, and ischemic stroke, with a cor

125 The pathologic indices of Alzheimer disease, cerebrovascular disease, and Lewy body disease accumulat

126 ed decreased risk of coronary heart disease, cerebrovascular disease, and overall CVD mortality in Ch

127 ease, which included coronary heart disease, cerebrovascular disease, and peripheral arterial disease

128 on; white matter lesions (WMLs), a marker of cerebrovascular disease; and cognitive functions.

129 ve had previous revascularization or carotid/cerebrovascular disease; and were more likely to have th

130 The consequences of cerebrovascular disease are among the leading health iss

131 INTRODUCTION: Patients with cerebrovascular disease are at increased risk for cognit

132 Coronary heart disease and cerebrovascular disease are leading causes of death in t

133 at the cognitive effects of the small vessel cerebrovascular disease are variable and not especially

134 ffects, their mechanisms and implications in cerebrovascular diseases are not known.

135 Cerebrovascular diseases are the most common neurologica

136 By 2013, 27 provinces had cerebrovascular disease as the leading cause, five had i

137 ole in determining sex-linked differences in cerebrovascular disease as well as having important heal

138 e immune signalling in the pathogenesis of a cerebrovascular disease, as well as strategies for its t

139 the preoperative evaluation of patients with cerebrovascular disease, as well as that of an intraoper

140 Cerebrovascular disease associated with ACTA2 mutations

141 ons found in inflammatory cardiovascular and cerebrovascular diseases associated with an elevated blo

142 d not have other clinical evidence of AF and cerebrovascular disease at baseline.

143 between major depressive disorder (MDD) and cerebrovascular disease at the cellular level.

144 ure, and status with respect to coronary and cerebrovascular diseases, atrial fibrillation, smoking,

145 cognized by traditional clinical features of cerebrovascular disease because brain microvascular dise

146 tain incident CVD (coronary heart disease or cerebrovascular disease) between the survey and the end

147 diseases--namely, type 2 diabetes, dementia, cerebrovascular disease, breast cancer, colorectal cance

148 rence to the MeDi is associated with reduced cerebrovascular disease burden.

149 1 mg/m(3) would have had a similar impact on cerebrovascular disease but one only half as great on is

150 e energy intake/obesity are risk factors for cerebrovascular disease, but it is not known if and how

151 vascular depression hypothesis, subclinical cerebrovascular disease can cause depression in older ad

152 severe liver disease, myocardial infarction, cerebrovascular disease, cardiac arrhythmias, dementia,

153 Microvascular disease, diabetic foot, cerebrovascular disease, cardiovascular disease, acute m

154 avian stenosis, peripheral vascular disease, cerebrovascular disease, cardiovascular disease, or surv

155 An influential model of how subcortical cerebrovascular disease causes cognitive dysfunction pos

156 of major coronary heart disease (CHD) and/or cerebrovascular disease (CBD) events in a large cohort o

157 groups with incidence of and mortality from cerebrovascular disease (CBVD) in a Mediterranean popula

158 ediction of coronary heart disease (CHD) and cerebrovascular disease (CeVD) can aid healthcare provid

159 re significantly higher for 18 patients with cerebrovascular disease (CeVD) than for 18 age- and gend

160 k of mortality from ischaemic heart disease, cerebrovascular disease, chronic obstructive pulmonary d

161 blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, chronic obstructive pulmonary d

162 The prevalence of diabetes, hypertension, cerebrovascular disease, chronic obstructive pulmonary d

163 disease, heart failure, cardiac arrhythmia, cerebrovascular disease, congenital heart disease, or ad

164 a low, intermediate or high likelihood that cerebrovascular disease contributed to cognitive impairm

165 cluding death from coronary heart disease or cerebrovascular disease, coronary revascularization, myo

166 Cerebrovascular disease (CVD) is consistently associated

167 nosed with Alzheimer's disease (AD), 11 with cerebrovascular disease (CVD), 9 with both (mixed pathol

168 of Alzheimer's disease (AD) and subcortical cerebrovascular disease (CVD).

169 sease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]) on long-term cardiovascul

170 Cardiovascular and cerebrovascular diseases (CVDs) related to overwork are

171 whereas Mexicans experienced higher rates of cerebrovascular disease deaths.

172 europathological examination with or without cerebrovascular disease, defined neuropathologically.

173 y of heart failure, coronary artery disease, cerebrovascular disease, diabetes mellitus, hypertension

174 ity burden of hypertensive heart disease and cerebrovascular disease, especially hemorrhagic stroke,

175 and the new occurrence of cardiovascular and cerebrovascular disease, especially the brain infarction

176 e same role in predicting cardiovascular and cerebrovascular diseases, especially in China.

177 9-23; specificity 96%, 94-98); pre-existing cerebrovascular disease (five cohorts; RR 1.6, 1.1-2.4;

178 The relation with cerebrovascular disease has not yet been closely examine

179 .86, 95% confidence interval: 0.83, 0.89) or cerebrovascular disease (hazard ratio = 0.82, 95% confid

180 art failure, peripheral vascular disease, or cerebrovascular disease (hazard ratio [95% confidence in

181 d ratio, 2.02; 95% CI, 1.02-3.97), and prior cerebrovascular disease (hazard ratio, 2.04; 95% CI, 1.0

182 95% confidence interval: 1.16 to 1.56), and cerebrovascular disease (hazard ratio: 1.36; 95% confide

183 presentations (coronary heart disease [CHD], cerebrovascular disease, heart failure, and peripheral v

184 Thal phase, Braak stage, cerebrovascular disease, hippocampal sclerosis and Patho

185 tributions of Alzheimer's disease pathology, cerebrovascular disease, hippocampal sclerosis and the a

186 Cerebrovascular disease (HR, 1.3; 95% CI, 1.2-1.4), chro

187 ted diagnoses (HR, 1.65; 95% CI, 1.26-2.17), cerebrovascular disease (HR, 1.95; 95% CI, 1.14-3.33), p

188 ciated with an increased hazard rate (HR) of cerebrovascular disease (HR, 3.52; 95% confidence interv

189 95% confidence interval [CI]: 1.45 to 1.54), cerebrovascular disease (HR: 1.07; 95% CI: 1.04 to 1.11)

190 ase (PVD), diabetes, ischemic heart disease, cerebrovascular disease, hypertension, and smoking, were

191 e diabetes mellitus, ischemic heart disease, cerebrovascular disease, hypertension, and smoking.

192 scular disease were older than those without cerebrovascular disease in all the groups except for tho

193 This results in an increased burden of cerebrovascular disease in CKD patients, who consistentl

194 Given the role of cerebrovascular disease in dementia risk, geographic pat

195 ifestyle was associated with protection from cerebrovascular disease in men, but there was no evidenc

196 nt periodontal inflammation-and incidence of cerebrovascular disease in men, independent of establish

197 to the post-mortem assessment and scoring of cerebrovascular disease in relation to vascular cognitiv

198 ed a genetic component to the development of cerebrovascular disease in SCA, but few candidate geneti

199 iated with a significantly increased rate of cerebrovascular disease in the combined or age-stratifie

200 their respective lesions than those without cerebrovascular disease in the context of comparable sev

201 vale (PFO), ischemic stroke, and subclinical cerebrovascular disease in the general population.

202 on the association between air pollution and cerebrovascular disease in the United States are limited

203 and the new occurrence of cardiovascular and cerebrovascular diseases in the study.

204 rt disease, peripheral arterial disease, and cerebrovascular disease, in an elderly male cohort.

205 hite matter hyperintensities, a biomarker of cerebrovascular disease, in several brain areas.

206 associations between neuroimaging markers of cerebrovascular disease, including lesion topography and

207 igh blood pressure (BP) is a risk factor for cerebrovascular disease, including stroke.

208 L4A1 or COL4A2 mutations suffer from diverse cerebrovascular diseases, including cerebral microbleeds

209 n barrier (BBB) is an important mechanism of cerebrovascular diseases, including neonatal cerebral hy

210 Depression and cerebrovascular disease influence each other, according

211 Cerebrovascular disease is 1 of the possible mechanisms

212 PURPOSE OF REVIEW: Cerebrovascular disease is a common cause of death and d

213 Concurrent cerebrovascular disease is a common neuropathological fi

214 Comorbidity of AD/SDAT and various types of cerebrovascular disease is a major theme in dementia res

215 Cerebrovascular disease is a significant and potentially

216 Cerebrovascular disease is common in head and neck cance

217 Dementia associated with cerebrovascular disease is common.

218 Inflammation that contributes to acute cerebrovascular disease is driven by the proinflammatory

219 Cerebrovascular disease is the third leading cause of de

220 diseases, including ischemic heart disease, cerebrovascular disease, ischemic stroke, hemorrhagic st

221 from a distant embolism rather than in situ cerebrovascular disease, leading to the recent formulati

222 cerebral alpha-synuclein scores, presence of cerebrovascular disease, MAPT haplotype, and APOE genoty

223 'Vascular Depression' hypothesis posits that cerebrovascular disease may predispose, precipitate or p

224 h levels of homocysteine are associated with cerebrovascular disease, monoamine neurotransmitters, an

225 h an increased risk of incident coronary and cerebrovascular disease morbidity and mortality.

226 [CI, 0.68 to 0.90]; P for trend < 0.001) and cerebrovascular disease mortality (HR, 0.70 [CI, 0.55 to

227 ease, two studies on both coronary heart and cerebrovascular disease mortality and one study on perip

228 France has the lowest present-day cerebrovascular disease mortality for both males and fem

229 t was found in participants aged <65 y or in cerebrovascular disease mortality for those aged >or=65

230 Analysis of cerebrovascular disease mortality revealed that Austria

231 The melanoma, NHL, and cerebrovascular disease mortality risks are possibly due

232 re consistent for coronary heart disease and cerebrovascular disease mortality.

233 harmful) to the risk for cardiovascular and cerebrovascular disease, mortality, or all-cause mortali

234 h atrial fibrillation, chronic lung disease, cerebrovascular disease, nonischemic cardiomyopathy, and

235 Eighty incident cases of cerebrovascular disease occurred from 27,506 person-year

236 n included the indication of atherosclerotic cerebrovascular disease (odds ratio [OR], 2.494), the in

237 diseases of the heart, malignant neoplasms, cerebrovascular diseases) of the top 4 leading causes of

238 ase, previous myocardial infarction, angina, cerebrovascular disease, older age, and male gender.

239 hese differences were associated with covert cerebrovascular disease on magnetic resonance imaging (M

240 c retinopathy OR macular edema AND stroke OR cerebrovascular disease OR coronary artery disease OR he

241 and discharged alive and free of documented cerebrovascular disease or preexisting atrial fibrillati

242 (odds ratio [OR], 0.31; 95% CI, 0.12-0.80), cerebrovascular disease (OR, 0.10; 95% CI, 0.01-0.78), c

243 ng disease (OR, 1.215; 95% CI, 1.125-1.312), cerebrovascular disease (OR, 1.172; 95% CI, 1.076-1.276)

244 r disease (such as congestive heart failure, cerebrovascular disease, or aortic stenosis), and among

245 Outpatients with coronary artery disease, cerebrovascular disease, or peripheral arterial disease

246 r risks of coronary heart disease (P=0.002), cerebrovascular disease (P<0.001), and venous thromboemb

247 r stroke included emergency status (P<0.02), cerebrovascular disease (P<0.02), and crossclamp time (P

248 Differentiating the cognitive effects of cerebrovascular disease, particularly small vessel disea

249 ars for the outcomes coronary heart disease, cerebrovascular disease, peripheral arterial disease, an

250 or shock, left main coronary artery disease, cerebrovascular disease, peripheral arterial disease, co

251 ars; 81% male) with coronary artery disease, cerebrovascular disease, peripheral artery disease, or a

252 se (CVD) events, ie, coronary heart disease, cerebrovascular disease, peripheral vascular disease, an

253 namic state or shock, several comorbidities (cerebrovascular disease, peripheral vascular disease, co

254 t (fatal or nonfatal coronary heart disease, cerebrovascular disease, peripheral vascular disease, or

255 Cerebrovascular disease present in 40.3% and cortical ma

256 forms of cognitive disorder associated with cerebrovascular disease, regardless of the specific mech

257 low-up of 5.1 years, cerebrovascular events (cerebrovascular disease-related death, ischemic stroke,

258 Cerebrovascular diseases represent up to 22% of secondar

259 ive radiotherapy, was associated with excess cerebrovascular disease risk in older patients.

260 s unknown whether radiotherapy increases the cerebrovascular disease risk in this population.

261 a (NHL) (RR = 2.69; 95% CI: 1.33, 5.45), and cerebrovascular disease (RR = 1.49; 95% CI: 1.11, 2.01).

262 mes in patients with and without symptomatic cerebrovascular disease (sCVD) undergoing heart transpla

263 impairment (VCI) is a heterogeneous group of cerebrovascular diseases secondary to large and small ve

264 e impairment and suggests that the impact of cerebrovascular disease should be considered with respec

265 s (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and

266 n in autonomic control of the vasculature in cerebrovascular disease states.

267 ic resonance imaging (MRI) manifestations of cerebrovascular disease, such as lacunes and white matte

268 o be related to other underlying subclinical cerebrovascular disease, such as white-matter disease or

269 an important role in the pathophysiology of cerebrovascular diseases-such as blood pressure and oxid

270 rt disease, venous thromboembolic event, and cerebrovascular disease than inactivity.

271 ease showed a lower prevalence of coincident cerebrovascular disease than patients with Alzheimer's d

272 and deaths from cardiovascular diseases and cerebrovascular diseases; the most stable association wa

273 ential role of choline in cardiovascular and cerebrovascular disease through its involvement in lipid

274 ith statins (69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet

275 tribution of cardiovascular disease (CV) and cerebrovascular disease to the risk for late-onset Alzhe

276 e, heart rhythm disturbances, heart failure, cerebrovascular disease, total CVD).

277 primary cause of coronary artery disease and cerebrovascular disease, two of the most common causes o

278 study (six studies on CHD, three studies on cerebrovascular disease, two studies on both coronary he

279 Cerebrovascular disease typically manifests with stroke,

280 secutive patients suspected or known to have cerebrovascular disease underwent 1.5-T brain MR imaging

281 Presence of cerebrovascular disease, vascular pathology and vascular

282 Therefore, we compared the prevalence of cerebrovascular disease, vascular pathology and vascular

283 The impact of small-vessel cerebrovascular disease, visualized as white matter hype

284 When cerebrovascular disease was also present, patients with

285 y of death resulting from cardiovascular and cerebrovascular disease was elevated, 4.2% versus 2.1% a

286 Cerebrovascular disease was quantified by measuring brai

287 istory of previous strokes, warfarin use, or cerebrovascular disease was recorded.

288 used to identify cases of Parkinsonism where cerebrovascular disease was the only pathological findin

289 ined as use in patients who had a history of cerebrovascular disease, weighed <60 kg, or were aged >/

290 p), the HRs of death from cardiovascular and cerebrovascular disease were 1.5 (95% CI, 1.4 to 1.7) an

291 se overall, acute myocardial infarction, and cerebrovascular disease were 3,500 (95% confidence inter

292 Patients with ischemic cerebrovascular disease were enrolled into our study.

293 ognitive impairment, and 280 cases with pure cerebrovascular disease were included for comparison.

294 st more than 18 years old without history of cerebrovascular disease were included.

295 Cases with cerebrovascular disease were older than those without ce

296 the PROGRESS trial, where 6105 patients with cerebrovascular disease were randomly assigned to either

297 ith moyamoya vasculopathy or atherosclerotic cerebrovascular disease who had undergone (15)O-water PE

298 who had a primary or secondary diagnosis of cerebrovascular disease, who underwent magnetic resonanc

299 or PAD are similar to those for coronary and cerebrovascular disease, with some differences in the re

300 o have this sign and are suspected of having cerebrovascular disease yields additional and complement